Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/05/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
96 |
| 05/03/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
97 |
| 11/10/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
97 |
| 08/06/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
101 |
| 05/12/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
93 |
| 12/05/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
94 |
